References
- Harrison S J, Cook G, Nibbs R J, Prince H M. Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Rev Anticancer Ther 2006; 6: 1769–1785
- Perez-Simon J A, Martino R, Alegre A, Tomas J F, De Leon A, Caballero D, et al. Chronic but not acute graft versus host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108
- Dhodapkar M V, Geller M D, Chang D H, Shimizu K, Fujii S, Dhodapkar K M, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003; 197: 1667–1676
- Redfern C H, Guthrie T H, Bessudo A, Densmore J J, Holman P R, Janakiraman N, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24: 3107–3112
- Hansson L, Abdalla A O, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte-macrophage colony stimulating factor, in early stage multiple myeloma patients. Clin Cancer Res 2007; 13: 1503–1510
- Lee J, Choi B, Kang H, Park M, Park J, Kim S, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimised myeloma cell lysates. Leuk Lymphoma 2007; 48: 2022–2031
- Rebmann V, Schutt P, Brandhurst D, Opalka B, Moritz T, Nowrousian M R, et al. Soluble MICA as an independent prognostic factor for the overall survival and progression free survival of multiple myeloma patients. Clin Immunol 2007; 123: 114–120
- Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol 2005; 35: 1155–1163
- Brimnes M K, Svane I M, Johnsen H E. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol 2006; 144: 76–84